Literature DB >> 11894034

Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival.

Dominique Elias1, Jean-Francois Ouellet, Thierry De Baère, Philippe Lasser, Alain Roche.   

Abstract

BACKGROUND: Some patients cannot undergo curative surgical procedures for liver metastases because of the risk of severe postoperative hepatic failure, which stems from a too-small future remaining liver (FRL). Preoperative portal vein embolization (PVE) is an effective means of creating hypertrophy of the FRL, thus permitting safe hepatic resection. The aim of this retrospective study was to investigate the long-term results of this technique.
METHODS: Sixty-eight patients underwent PVE. Of those, 60 (88%) subsequently underwent hepatic resection. Indication for PVE was an estimated FRL ratio (assessed by volumetric computed tomography) of less than 30%. However, if the patient had undergone multiple courses of chemotherapy, the threshold was 40%. The origin of the primary neoplasm was colorectal in 41 patients (68%); in the remaining 19 (32%), the primary neoplasms originated at other sites.
RESULTS: Mean growth of the estimated FRL measured by computed tomography 1 month after PVE was 13%. Major complications after hepatectomy occurred in 27% of the patients, and the operative mortality rate was 3%. For the 60 patients who underwent PVE followed by hepatic resection, the 5-year overall survival rate and the disease-free survival rate were 34% and 24%, respectively. The 5-year overall survival rate and the disease-free survival rate of patients with colorectal metastases only were 37% and 21%, respectively.
CONCLUSIONS: The long-term survival rate after PVE followed by resection is comparable with the survival rate obtained after resection without preoperative PVE. The 5-year survival rate of patients undergoing PVE followed by hepatectomy justifies the use of this technique. This technique thus increases the suitability of resection as a treatment choice for patients with liver metastases. PVE should number among the therapeutic options available to every hepatic surgeon.

Entities:  

Mesh:

Year:  2002        PMID: 11894034     DOI: 10.1067/msy.2002.120234

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  37 in total

Review 1.  The surgical treatment of hepatic metastases in colorectal carcinoma.

Authors:  Ulf Peter Neumann; Daniel Seehofer; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2010-05-14       Impact factor: 5.594

Review 2.  Protection of the liver during hepatic surgery.

Authors:  Pierre-Alain Clavien; Jean Emond; Jean Nicolas Vauthey; Jacques Belghiti; Ravi S Chari; Steven M Strasberg
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

3.  [Intra-arterial treatment of liver metastases from colorectal carcinoma].

Authors:  O Pellerin; J-F Geschwind
Journal:  J Radiol       Date:  2011-09-01

Review 4.  Preoperative portal vein embolization in liver cancer: indications, techniques and outcomes.

Authors:  Romaric Loffroy; Sylvain Favelier; Olivier Chevallier; Louis Estivalet; Pierre-Yves Genson; Pierre Pottecher; Sophie Gehin; Denis Krausé; Jean-Pierre Cercueil
Journal:  Quant Imaging Med Surg       Date:  2015-10

5.  Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure.

Authors:  Universe Leung; Amber L Simpson; Raphael L C Araujo; Mithat Gönen; Conor McAuliffe; Michael I Miga; E Patricia Parada; Peter J Allen; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; Yuman Fong; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2014-06-25       Impact factor: 6.113

Review 6.  Portal vein embolization before major hepatectomy.

Authors:  Hai Liu; Yong Fu
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

7.  Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate.

Authors:  Elie Oussoultzoglou; Philippe Bachellier; Edoardo Rosso; Radu Scurtu; Ioan Lucescu; Michel Greget; Daniel Jaeck
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

8.  How can we safely climb the ALPPS?

Authors:  Norihiro Kokudo; Junichi Shindoh
Journal:  Updates Surg       Date:  2013-09

Review 9.  Current treatment for liver metastases from colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

10.  Management of hepatic metastases from colorectal cancer.

Authors:  Ketan R Sheth; Bryan M Clary
Journal:  Clin Colon Rectal Surg       Date:  2005-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.